Skip to content

Dr. Reddy’s launches generic version of Lamictal XR

Dr. Reddy’s Laboratories has released lamotrigine extended-release tablets, an anti-seizure medication. The India-based drug maker said Wednesday that its lamotrigine product is a therapeutically equivalent generic version of GlaxoSmithKline’s Lamictal XR tablets. Dr.

HYDERABAD, India — Dr. Reddy’s Laboratories has released lamotrigine extended-release tablets, an anti-seizure medication.

The India-based drug maker said Wednesday that its lamotrigine product is a therapeutically equivalent generic version of GlaxoSmithKline’s Lamictal XR tablets.

Dr. Reddy’s lamotrigine XR tablets come in dosages of 25 mg, 50 mg, 100 mg, 200 mg and 300 mg are available as unit-of-use bottles of 30s.

The Lamictal XR brand and generic had combined U.S. sales of about $300.5 million for the 12 months ended in April, according to IMS Health data cited by Dr. Reddy’s.

Lamotrigine is indicated for the treatment of epileptic seizures in adults and children. The drug also is used in the treatment of adults with bipolar disorder.

Latest

H-E-B embodies purposefulness

H-E-B embodies purposefulness

During remarks delivered at last month’s FMI Midwinter Executive Conference, Boyan, who is also the association’s chairman, spoke about what motivates the company.

The K-shaped economy’s hidden truths

The K-shaped economy’s hidden truths

New research from the Kearney Consumer Institute uncovers some hidden aspects of the trend, which, of course, has serious implications for both mass market retailers and consumer packaged goods companies.